Enhancing tumor drug delivery: targeting nucleolin with liposomes for improved therapeutic efficacy
Main Article Content
Abstract
Nucleolin (NCL) is a multifunctional protein that plays a significant role in cancer development and progression. Nucleolin's expression on both endothelial and cancer cells makes it a strategic target for cancer therapy and drug delivery applications. This study aims to develop dexamethasone-loaded liposomes (LP-Dexa) coated with an affinity peptide for NCL (F3/LP-Dexa) to target cancer and endothelial cells and reduce tumor-associated inflammation. LP-Dexa were prepared using lipid film hydration followed by the extrusion method and functionalized with F3 peptide via thiol-maleimide linkage. Internalization by bEnd.3 cells (endothelial cells isolated from brain tissue derived from a mouse with endothelioma) was assessed using immunofluorescence and flow cytometry at various intervals. NCL protein and gene expression were analyzed post-treatment using immunofluorescence, flow cytometry, and real-time PCR. The anti-inflammatory effect was evaluated by measuring monocyte chemoattractant protein-1 (MCP-1) expression via Western blot. NCL expression increased two-fold in TNF-α-activated bEnd.3 cells compared to controls. F3/LP-Dexa showed efficient internalization and significantly reduced NCL mRNA and MCP-1 protein levels without inducing cytotoxicity at lower dexamethasone concentrations. Targeting NCL with F3/LP-Dexa offers a novel strategy for intracellular drug delivery to both cancer cells and activated endothelial cells, potentially reducing tumor growth and vascular inflammation while advancing therapeutic options for cancer.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.